drugset

drugset / Trial / NCT02195232

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232 ↗

Phase 2/3 Completed 64 enrolled Jeffrey Zwicker, MD National Heart, Lung, and Blood Institute (NHLBI) · collab Quercegen Pharmaceuticals · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.

Timeline

Start: 2015-01
Primary completion: 2018-12
Completion: 2019-10-22

Publications

Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R; CATIQ Investigators11. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019 Feb 21;4(4):e125851. doi: 10.1172/jci.insight.125851. eCollection 2019 Feb 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Isoquercetin	Small molecule	500 mg	Oral
Subject	Isoquercetin	Small molecule	1000 mg	Oral

Indications